Ultragenyx Pharmaceutical (RARE) Other Non-Current Liabilities (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Other Non-Current Liabilities data on file, last reported at $42.0 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 145.28% year-over-year to $42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.0 million (up 145.28% YoY) and the FY2025 annual result came in at $44.0 million, up 158.82% from the prior year.
• Other Non-Current Liabilities slipped to $42.0 million in Q1 2026 per RARE's latest filing, from $44.0 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $881.0 million in Q2 2023 and bottomed at $3.8 million in Q2 2022.
• The 5-year median for Other Non-Current Liabilities is $42.0 million (2026), against an average of $349.1 million.
• Peak annual rise in Other Non-Current Liabilities reached 59575.46% in 2022, while the deepest fall reached 98.9% in 2022.
• Tracing RARE's Other Non-Current Liabilities over 5 years: stood at $875.4 million in 2022, then declined by 1.5% to $862.3 million in 2023, then sank by 98.03% to $17.0 million in 2024, then jumped by 158.82% to $44.0 million in 2025, then declined by 4.55% to $42.0 million in 2026.
• Per Business Quant, the three latest RARE Other Non-Current Liabilities figures stand at $42.0 million (Q1 2026), $44.0 million (Q4 2025), and $763.7 million (Q3 2025).

Peer Comparison